Evidence map›Paper›PMID 38400181›Full record

ArticleVaccines2024

Polymeric Nanoparticles as Oral and Intranasal Peptide Vaccine Delivery Systems: The Role of Shape and Conjugation.

Prashamsa Koirala, Ahmed O Shalash, Sung-Po R Chen, Mohammad O Faruck, Jingwen Wang, Waleed M Hussein, Zeinab G Khalil, Robert J Capon, Michael J Monteiro, Istvan Toth and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Prashamsa KoiralaSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0003-4436-364X
Ahmed O ShalashSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0003-3819-4798
Sung-Po R ChenAustralian Institute of Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0003-4257-3889
Mohammad O FaruckSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Jingwen WangSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Waleed M HusseinSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0001-5392-1880
Zeinab G KhalilInstitute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia.ORCID 0000-0002-9285-1720
Robert J CaponInstitute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia.ORCID 0000-0002-8341-7754
Michael J MonteiroAustralian Institute of Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia.
Istvan TothSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Mariusz SkwarczynskiSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0001-7257-807X
The University of Queensland · AU

Funding

National Health and Medical Research Council APP1132975
6 · The paper itself

Abstract

Mucosal vaccines are highly attractive due to high patient compliance and their suitability for mass immunizations. However, all currently licensed mucosal vaccines are composed of attenuated/inactive whole microbes, which are associated with a variety of safety concerns. In contrast, modern subunit vaccines use minimal pathogenic components (antigens) that are safe but typically poorly immunogenic when delivered via mucosal administration. In this study, we demonstrated the utility of various functional polymer-based nanostructures as vaccine carriers. A Group A

Indexed as

conjugatesGroup A Streptococcusintranasal deliverymucosal immunologynanoparticlesoral deliverypeptidesphysical mixturevaccines

Identifiers

PMID38400181
PMCPMC10893271
OpenAlexW4391846607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.